US20040062724A1 - Erodible film for treating the surfaces of teeth - Google Patents
Erodible film for treating the surfaces of teeth Download PDFInfo
- Publication number
- US20040062724A1 US20040062724A1 US10/444,512 US44451203A US2004062724A1 US 20040062724 A1 US20040062724 A1 US 20040062724A1 US 44451203 A US44451203 A US 44451203A US 2004062724 A1 US2004062724 A1 US 2004062724A1
- Authority
- US
- United States
- Prior art keywords
- strip
- layer
- erodible
- polymer
- water soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- This invention relates to the cosmetic or therapeutic treatment of teeth, and more specifically to an adherent, erodible film that provides an active ingredient agent to teeth surfaces for a prolonged and controlled period of time.
- a tooth is composed of a protective, hard enamel outer layer and an inner dentin layer.
- the enamel layer is typically opaque white or slightly off-white in color.
- This layer is composed of hydroxyapatite mineral crystals and is somewhat porous, allowing staining agents and discoloring substances to permeate the enamel and discolor teeth.
- staining agents and discoloring substances In particular, certain foods, tobacco products and liquids such as tea and coffee tend to stain teeth. These substances accumulate on the surface and form a film on the teeth, and will then permeate into the enamel layer. This problem occurs over many years, imparting a noticeable discoloration of the enamel layer.
- 6,419,906 B1 describes a flexible film which when applied to stained teeth is hydrated by saliva and is effective in such form to whiten teeth.
- the film comprises an anhydrous water hydratable ethylene oxide polymer matrix containing a solid peroxide whitening agent whereby, upon placing and positioning on stained teeth, the peroxide is solubilized and activated by the saliva present in the oral cavity.
- composition of the bi-layered and multi-layered devices consists of an enamel adherent, water soluble, polymeric layer containing a tooth whitening agent or other active compound and a coated, erodible backing layer that controls the desired residence time. Since the devices of the current invention can provide a longer contact time with a stained tooth surface before eroding, it is expected that lower and safer amounts of whitening agents can be used to accomplish similar or superior results than attained by other commercial products.
- An important aspect of the present invention is an erodible multilayered strip comprising at least two layers, a first layer comprises a water soluble polymer or combination of polymers that adheres to moist enamel surfaces. A second layer is water erodible and controls the residence time that the strip remains adhere to the enamel surface.
- This erodible strip is preferably shaped to conform to an individual tooth or a row of teeth.
- An important embodiment of the present invention involves erodible adhesive a mucoadhesive, erodible multi-layered device comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time of the device.
- the first layer preferably comprises a tooth-whitening agent, at least one water-soluble film-forming polymer in combination with at least one mucoadhesive polymer; and said second, water-erodible non-adhesive backing layer comprises a precast film containing at least one of hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, polyethylene glycol, polyethylene oxide, and ethylene oxide-propylene oxide co-polymer, said backing layer being coated with at least one hydrophobic polymer, alone or in combination with at least one hydrophilic polymer, such that the backing layer is bioerodible.
- An important aspect of the present invention is a mucoadhesive, erodible multi-layered device comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time of the device.
- the first layer comprises a tooth-whitening agent (most preferably carbamide peroxide), at least one water-soluble film-forming polymer in combination with at least one mucoadhesive polymer.
- Said second, water-erodible non-adhesive backing layer comprises a precast film containing at least one of hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, polyethylene glycol, polyethylene oxide, and ethylene oxide-propylene oxide co-polymer.
- This backing layer is coated with at least one hydrophobic polymer, alone or in combination with at least one hydrophilic polymer, such that the backing layer is bioerodible.
- the second water-erodible non-adhesive backing layer acts as a casting and support surface on which the adhesive layer is prepared.
- a premade film of hydroxypropyl methyl cellulose in combination with a coating consisting of at least one hydrophobic polymer selected from the family of quaternary ammonium acrylate/methacrylate co-polymers, (Eudragit RS) ethyl cellulose and methyl cellulose, alone or in combination with at least one hydrophilic polymer, selected from the group consisting of polyvinyl pyrrolidone, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and polyvinyl alcohol.
- hydrophobic polymer selected from the family of quaternary ammonium acrylate/methacrylate co-polymers, (Eudragit RS) ethyl cellulose and methyl cellulose
- hydrophilic polymer selected from the group consisting of polyvinyl pyrrolidone, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and polyvinyl alcohol
- a unique, erodible, layered device that adheres to tooth enamel surfaces.
- the device is most applicable for the cosmetic treatment of stained teeth, by delivering a whitening agent or combination of agents thereof for a controlled period of time.
- the device can also be used for the delivery of fluoride ions and phosphates for the preventative treatment of caries and tartar accumulation, respectively.
- the device initially adheres to a moist tooth surface due to the hydration and partial solubilization of the water soluble polymer layer.
- the whitening agent that is dispersed throughout this polymeric layer is then activated as it comes in contact with saliva and is released to the underlying surface.
- the erosion rate of the device is controlled by the coated backing layer, which affects the amount of time the whitening agent remains in contact with the enamel surface.
- the main purpose of the backing layer is to slow down the dissolution of the water-soluble polymeric layer containing a whitening agent, and therefore maximizing the direct contact time and unidirectional delivery to the tooth surface.
- the composition of the backing layer is easily adjusted to provide variable erosion rates from one half hour to several hours.
- the layered device is essentially totally erodible, and therefore does not require removal after the appropriate treatment time.
- the Residence Time as defined above is difficult to quantitatively ascertain.
- One visual method is to apply the layered device to the teeth surface and periodically observe the covered surface using a mirror and assess approximately how much residue remains on the surface.
- the adhesive swells and starts to dissolve and fall off the teeth surface.
- the actual residence time on each surface is controlled primarily by the flow of saliva to the surface and any friction created by interaction with the internal surface of the lips.
- the polymeric coating layer that adheres to the tooth enamel is composed of one or more adhesive polymers, an appropriate whitening agent and a plasticizer. This coating may also contain an antioxidant, a preservative and a taste-masking flavor.
- the adhesive polymers can be any water soluble, FDA approved polymer for oral applications that sticks to an enamel surface when in contact with a moist tooth surface.
- the adhesive polymers may comprise hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxyethylmethyl cellulose, sodium carboxymethyl cellulose, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, polyacrylic acid, polyethylene oxide, alone or in combination thereof.
- the preferred adhesive polymers are hydroxyethyl cellulose and polyvinyl pyrrolidone since they exhibit rapid and effective adhesion to enamel when in contact with a moist tooth surface.
- the molecular weight of the adhesive polymer is also important, since it must be large enough so that an integral film can form, but not so large that immediate interfacial solubilization and adhesion to the enamel surface is impaired.
- Typical average molecular weights range between 50,000 and 1,500,000 Daltons, and preferably between 50,000 and 500,000.
- the whitening agents suitable for the practice of the present invention include peroxides, metal chlorites, perborates, percarbonates, peroxyacids, persulfates, alone or in combination thereof.
- Suitable peroxide compounds include hydrogen peroxide, carbamide peroxide, calcium peroxide, and mixtures thereof.
- the preferred peroxide is carbamide peroxide.
- Suitable metal chlorites include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite, and potassium chlorite.
- the preferred chlorite is sodium chlorite.
- a preferred percarbonate is sodium percarbonate, and the preferred persulfates are oxones.
- the rate at which the whitening agent is solubilized and subsequently released to a tooth surface is controlled by varying the film thickness, polymer properties such as structure and molecular weight, type and properties of whitening agent and the concentration of the whitening agent.
- the concentration of the whitening agent typically varies from about 0.1% to about 30% by weight of the total layered device, and preferably from about 0.5% to about 20% by weight.
- a plasticizer useful for purposes of the present invention is selected from glycols such as propylene glycol, polyethylene glycol, polyhydric alcohols such as glycerin and sorbitol and glycerol esters such as glycerol triacetate.
- the plasticizer comprises about 0.2% to about 30% by weight of the film of the present invention and preferably about 0.5% to about 10% by weight.
- Glycerin and propylene glycol are the preferred plasticizers for use in the present invention as well as polyethylene glycol.
- the preferred molecular weights for polyethylene glycol are in the range of 200-600 Daltons.
- a colorant or opacifier can be incorporated in the adhesive layer or any of the layers of this device for use as an appearance enhancer.
- the colorant or opacifier comprises about 0.01% to about 10% by weight of the film of the present invention and preferably about 0.03% to about 1% by weight. Colors and opacifiers may also be used to help distinguish the non-adhesive backing layer from the enamel adhering layer. Some opacifiers include titanium dioxide, zinc oxide, zirconium silicate and others.
- a plasticizer, and colorants there may also be included in the adhesive film matrix a minor amount, e.g., 0.01 to 2% by weight, of ingredients such as preservatives, antioxidants, and flavors.
- the backing layer solution is composed of a mixture of a hydrophobic polymer, such as ethyl cellulose, methyl cellulose, propyl cellulose or other related polymers and copolymers, anionic, cationic and neutral polymers and copolymers of methyl methacrylate under the trade name EUDRAGIT®, and a water soluble polymer such as polyvinyl pyrrolidone, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol or any other water soluble polymer that can be completely commixed with the hydrophobic polymer(s), dissolved in ethanol or other suitable organic solvent.
- a hydrophobic polymer such as ethyl cellulose, methyl cellulose, propyl cellulose or other related polymers and copolymers, anionic, cationic and neutral polymers and copolymers of methyl methacrylate under the trade name EUDRAGIT®
- a water soluble polymer such as
- the ratio of the hydrophobic to the hydrophilic polymer is adjusted to increase or decrease the desired residence time that the device remains on the teeth before complete erosion.
- the ratio of hydrophobic to hydrophilic polymer ranges from 0.5:1 to 10:1 by weight, and more preferably 1.5:1 to 3:1 by weight.
- the backing layer solution may also contain a plasticizing agent, such as propylene glycol, polyethylene glycol, or glycerin, in a small amount, 0.1 to 2.0% by weight, in order to improve the flexibility and conformability of the resultant layered film and to adjust the erosion rate of the device.
- a plasticizing agent such as propylene glycol, polyethylene glycol, or glycerin
- Colors and opacifiers may also be added to help distinguish the non-adhesive backing layer from the enamel adhering layer.
- these solutions are cast and processed into a thin film by techniques known in the art, such as by film dipping, film coating, film casting, spin coating, or spray drying. These films are produced on an appropriate support at the desired thickness and dried using an oven.
- the primary support can be a polymer-coated paper, Mylar or any other appropriate non-deformable and impervious surface.
- the preferable primary support is coated paper.
- the primary support's casting surface must hold the film dimensionally stable during the coating and drying processes, but allow the resulting composite film to release when desired.
- the actual casting surface for these solutions may be the primary support or another layer of the device being produced, such as the precast film layer or a freshly cast adhesive or backing layer.
- the amount of coating solutions applied ranges between 0.01 to 1.5 mm, and most preferably between 0.05 and 0.4 mm for the backing layer and between 0.8 and 1.3 mm for the adhesive layer.
- the amount of solids present in the coating solutions, the resulting solution viscosity and coating thickness applied determine the amount of coating film to be deposited on the casting surface.
- the final layered device will consist of an adhesive layer and a hydrophobic layer with or without a precast hydroxypropylmethyl cellulose (HPMC) film in-between.
- HPMC hydroxypropylmethyl cellulose
- the adhesive layer is formed on an appropriate primary support.
- the backing layer is formed on a water soluble, polymeric precast film of HPMC.
- the two films are then laminated, with the hydrophobic layer either on the outside or in the middle of the final composite film, using an appropriate binding solution such as polyvinylpyrrolidone dissolved in a water/ethanol mixture.
- This multi-layered film can be either peeled away from the primary support and cut into the desired shape or cut with the primary support still attached.
- the backing layer is formed on an appropriate primary support.
- a precast film of HPMC is then laminated to the backing layer using binding solution consisting of polyvinylpyrrolidone dissolved in a water/ethanol mixture.
- binding solution consisting of polyvinylpyrrolidone dissolved in a water/ethanol mixture.
- a distinct binding layer typically composed of polyvinylpyrrolidone is formed on top of the HPMC precast film.
- the adhesive layer is formed on top of the binding layer. This resulting multi-layer film is then further processed as outlined above.
- the adhesive layer is formed on an appropriate primary support by the casting methods previously described.
- the backing layer is then formed directly on top of the adhesive layer. This two-layer film is then further processed as outlined above.
- the backing layer is formed on an appropriate primary support by the casting methods previously described
- the adhesive layer is then formed directly on top of the backing layer and the resulting bilayered product is further processed as outlined above.
- each layer will affect the residence time of the device.
- the hydrophobic layer composition and thickness are the most important parameters in controlling the residence time.
- inclusion of the water soluble, polymeric precast film as one of the layers of the device will also increase the residence time, since the overall thickness of the device is increased.
- the total thickness of the device is also an important consideration in regards to user acceptance. A very thick device becomes more noticeable with respect to “mouth feel”, and may cause the user to discontinue its use prematurely, thus compromising efficacy.
- the total thickness of the device will also affect its ability to conform and adhere to teeth in an efficient manner.
- thin films are preferred since they can be easily applied and bent around the teeth, minimizing the amount of unattached area in the form of edges and comers that could cause the film to be accidentally pulled off the teeth.
- the film is too thin, it will begin to lose tensile strength and rip during its application.
- the thickness of the adhesive layer is between 50 ⁇ and 300 ⁇ , and more preferably between 60 ⁇ and 140 ⁇ .
- the thickness of the backing layer is between 50 ⁇ and 300 ⁇ , and more preferably between 60 ⁇ and 100 ⁇ .
- the thickness of the precast layer if used to produce a multilayered device is between 25 ⁇ and 200 ⁇ , and more preferably between 50 ⁇ and 100 ⁇ .
- the overall thickness of the device is between 75 ⁇ and 500 ⁇ , and more preferably between 125 ⁇ and 300 ⁇ .
- a 180.0 gram batch of placebo adhesive solution was prepared using 10.0 grams hydroxyethyl cellulose (Natrosol 250L NF; Hercules), 10.0 grams polyvinyl pyrrolidone (PVP; Povidone P-1416; Spectrum), 0.65 grams sodium benzoate (Spectrum), 0.65 grams propylene glycol (Spectrum), and 158.7 grams deionized and 0.22 ⁇ -filtered water. This solution was used in Example 11 below.
- a 29.87 gram batch of active adhesive solution was prepared using 4.37 grams hydroxyethyl cellulose (Natrosol 250L NF; Hercules), 1.80 grams PVP (Povidone P-1416; Spectrum), 0.09 grams sodium benzoate (Spectrum), 0.09 grams propylene glycol (Spectrum), 2.70 grams carbamide peroxide (Spectrum), and 20.82 grams deionized and 0.22 ⁇ -filtered water. This solution was used in Examples 12 and 13 below.
- a 25.94 gram batch of active adhesive solution was prepared using 3.51 grams hydroxyethyl cellulose (Natrosol 250L NF; Hercules), 1.66 grams PVP (Povidone P-1416; Spectrum), 0.08 grams sodium benzoate (Spectrum), 0.08 grams propylene glycol (Spectrum), 2.49 grams carbamide peroxide (Spectrum), and 18.12 grams deionized and 0.22 ⁇ -filtered water. This solution was used in Examples 14 and 15 below.
- a 46.84 gram batch of active adhesive solution was prepared using 2.70 grams hydroxyethyl cellulose (Natrosol 250L NF; Hercules), 1.35 grams PVP (Povidone P-1416; Spectrum), 0.15 grams sodium benzoate (Spectrum), 0.15 grams propylene glycol (Spectrum), 2.70 grams carbamide peroxide (Spectrum), 1.95 grams sodium alginate, and 37.84 grams deionized and 0.22 ⁇ -filtered water. This solution was used in Examples 16 and 17 below.
- a 19.0 gm batch of backing solution was prepared using 2.0 grams of ethyl cellulose (Ethocel Premium Std 7; Dow Chemical), 1.0 grams of HPMC (Methocel E5 Prem LV; Dow Chemical), 1.0 gram Adams Extract Red Food Color, and 15.0 grams ethanol (190 proof; USP; Spectrum).
- This backing solution was used in Examples 11, 15, and 18 below.
- a 16.5 gram batch of backing solution was prepared using 1.1 grams of ethyl cellulose, 1.1 grams of HPMC, 0.9 grams Adams Extract Red Food Color, and 13.4 grams ethanol (190 proof, USP; Spectrum). This backing solution was used to make Examples 16 and 17 below.
- a 19.8 gram batch of backing solution was prepared using 2.2 grams of ethyl cellulose, 1.1 grams of HPMC, and 16.5 grams ethanol (190 proof, USP; Spectrum). This backing solution was used to make Examples 12, 13, 19, and 20 below.
- a 25.2 gram batch of backing solution was prepared using 1.8 grams of ethyl cellulose, 1.8 grams of HPMC, and 21.6 grams ethanol (190 proof, USP; Spectrum). This backing solution was used to make Examples 21 and 22 below.
- a 52.7 gram batch of laminating solution was prepared using 6.32 grams PVP (P1416; Spectrum), 23.19 grams ethanol (190 proof, USP; Spectrum), and 23.19 grams deionized and 0.22 ⁇ -filtered water.
- the precast HPMC film used in several embodiments of this device was typically a 100 ⁇ thick sheet called EM1100 from Polymer Films. In some embodiments, it was stretched on a paper-and-foil frame of a Werner Mathis AG Lab Coater, type LTF, and a backing solution selected from Examples 5-8 was poured on top and doctor-bladed at a 0.25 mm setting, then dried in the oven section of the Lab Coater.
- a composite device was made by doctor-blading the adhesive solution of Example 1 into a film using the Lab Coater.
- the casting was performed on a polymer-coated paper from Fortifiber, which was put on the paper and foil frame of the Lab Coater, with a doctor blade setting of 1.76 mm.
- the film was automatically dried in the oven portion of the Lab Coater, and a smooth, integral layer of deposited, adhesive polymer resulted.
- a layer of backing solution from Example 5 was doctor-bladed on top of the precast HPMC film (Example 10) using a 0.25 mm setting.
- the two films were then laminated together using the laminating solution described in Example 9 and pressure from a roller, followed by drying in the Lab Coater oven.
- the film was cut either before or after removal from the coated paper and upon application to a moist tooth surface, the film stuck well.
- a composite device was made as in Example 11, except using the adhesive of Example 2, with doctor-blade setting of 1.00 mm, and the backing solution of Example 7. After cutting and removal from the casting coated paper, the resulting film also stuck well to teeth.
- Another composite device was made by putting a backing layer of 2:1 ethyl cellulose to HPMC as described in Example 7 on polymer-coated paper (from Fortifiber) and then putting a layer of whitening adhesive (Example 2) on top of it.
- the backing layer was doctor-bladed at a 0.43 mm setting and the adhesive was doctor-bladed at a setting of 1.30 mm. This film after removal from the paper and cutting, stuck immediately and firmly to teeth, conformed extremely well, and eroded away without notice.
- a composite device composed of only an adhesive layer was made using the process outlined in Example 11, except the adhesive of Example 3 was used and with a doctor blade setting of 1.30 mm.
- a test was done to determine the whitening efficacy of this adhesive layer alone as compared to the competitive product Crest Whitestrips. Both products were dampened and pressed onto a coffee-stained white cup. They were removed after 16 hours. The amount of whitening was compared and ranked by eight individuals who did not know which device did which whitening. The results shown below indicate that the adhesive layer containing a whitening agent is as effective if not better than one competitive product.
- Adhesive only: 5 firsts, 1 tie, and 2 seconds; relative average score 1.38
- a composite device was made by putting a layer of active adhesive from Example 3 on a polymer-coated paper (Fortifiber) and then putting a layer of backing solution from Example 5 on top of it.
- the adhesive was doctor-bladed at settings of 1.30 mm.
- the backing layer was spread thinly onto the surface of the dried adhesive film using a spatula and then dried. This resulting film after removal from the coated paper stuck well to the teeth.
- a composite device was made as in Example 11, except using the adhesive of Example 4 and with a doctor blade setting of 1.30 mm and the backing solution of Example 6 with a doctor blade setting of 0.25 mm. A strip of this film after removal from the surface of the coated paper and cutting, lasted about 11 ⁇ 2 hours on the front teeth.
- a composite device was made as in Example 15, except using the adhesive of Example 4 and the backing solution of Example 6. A strip of this film after removal from the surface of the coated paper and cutting, lasted about 1 hour on the front teeth.
- a composite device was made as in Example 11, except using the adhesive of Example 3 without the tooth whitening agent, carbamide peroxide, and doctor blade settings of 1.30 mm. After processing, this placebo film visually seemed similar to the active films and upon removal from the coated paper and cutting, stuck comparably to the teeth.
- a composite device was made as in Example 11, except using the adhesive of Example 4, a doctor blade setting of 1.30 mm, and the backing solution of Example 7.
- a composite device was made as in Example 15, except using the adhesive of Example 4, with a doctor blade setting of 1.30 mm, and the backing solution of Example 7. The resulting film after removal from the coated paper and cutting, lasted more than 1 ⁇ 2 hour on the front teeth.
- a composite device was made as in Example 11, except using the adhesive of Example 4, with doctor blade setting of 1.30 mm, and the backing solution of Example 8. The resulting film after removal from the coated paper and cutting, lasted about 11 ⁇ 2 hours on the front teeth.
- a composite device was made as in Example 15, except using the adhesive of Example 4, with doctor blade setting of 1.30 mm, and the backing solution of Example 8. The resulting film, after removal from the coated paper and cutting, lasted about 1 hour on the front teeth.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is a continuation-in-part and is based on and claims priority from U.S. patent application Ser. No. 09/931,319, filed Aug. 16, 2001 and is incorporated herein by reference.
- This invention relates to the cosmetic or therapeutic treatment of teeth, and more specifically to an adherent, erodible film that provides an active ingredient agent to teeth surfaces for a prolonged and controlled period of time.
- A tooth is composed of a protective, hard enamel outer layer and an inner dentin layer. The enamel layer is typically opaque white or slightly off-white in color. This layer is composed of hydroxyapatite mineral crystals and is somewhat porous, allowing staining agents and discoloring substances to permeate the enamel and discolor teeth. In particular, certain foods, tobacco products and liquids such as tea and coffee tend to stain teeth. These substances accumulate on the surface and form a film on the teeth, and will then permeate into the enamel layer. This problem occurs over many years, imparting a noticeable discoloration of the enamel layer.
- There have been numerous methods in the prior art relating to teeth whitening, including brushing the teeth using dentifrices containing an effective oxidizing agent such as peroxide. These types of compositions are disclosed in U.S. Pat. No. 5,256,402. More recently, several over-the-counter teeth whitening systems have become available and have gained in popularity as an alternative cosmetic treatment to teeth whitening procedures conducted by a professional. One such product is comprised of a thin strip of plastic film that has a tooth whitening composition applied to the surface as described in U.S. Pat. Nos. 5,894,017, 5,891,453 and 6,045,811. In addition, U.S. Pat No. 6,419,906 B1 describes a flexible film which when applied to stained teeth is hydrated by saliva and is effective in such form to whiten teeth. The film comprises an anhydrous water hydratable ethylene oxide polymer matrix containing a solid peroxide whitening agent whereby, upon placing and positioning on stained teeth, the peroxide is solubilized and activated by the saliva present in the oral cavity. These aforementioned systems produce a whitening effect when applied to stained teeth; however, the strips must be removed after a specified period of time. U.S. patent application Ser. No. 09/931,319 teaches the administration of pharmaceutically active compounds using a multi-layered mucoadhesive erodible drug delivery device. Although this reference relates to an oral pharmaceutical application unrelated to teeth whitening, one important teaching is that the length of time the device remains on the mucosal surface before complete erosion, the “residence time”, is easily modified by alterations of the backing layer. It is this teaching that will be utilized and adapted to the present invention relating to an erodible tooth-whitening strip. In the area of cosmetic dentistry, there is an ongoing need to improve the whitening efficiency and to provide more user-friendly over-the-counter products.
- One object of the present invention is to provide a novel, cost-effective, erodible, layered device that adheres to the moist surfaces of teeth and delivers an active agent for a controlled period of time. Another object of the present invention is to provide a convenient, user-friendly, erodible, layered device that adheres to the moist teeth surfaces and delivers a tooth whitening agent to the underlying stained surfaces. A further object of this invention is to provide a tooth whitening device that is easily applied without breaking or leaving any unwanted residue on the hands. A further object of the present invention is to provide a flexible, layered device that conforms and adheres intimately and securely to the entire tooth surface, minimizing the exposure of any excess whitening agent to the surrounding gums as found with other competitive products.
- The composition of the bi-layered and multi-layered devices consists of an enamel adherent, water soluble, polymeric layer containing a tooth whitening agent or other active compound and a coated, erodible backing layer that controls the desired residence time. Since the devices of the current invention can provide a longer contact time with a stained tooth surface before eroding, it is expected that lower and safer amounts of whitening agents can be used to accomplish similar or superior results than attained by other commercial products.
- An important aspect of the present invention is an erodible multilayered strip comprising at least two layers, a first layer comprises a water soluble polymer or combination of polymers that adheres to moist enamel surfaces. A second layer is water erodible and controls the residence time that the strip remains adhere to the enamel surface. This erodible strip is preferably shaped to conform to an individual tooth or a row of teeth.
- An important embodiment of the present invention involves erodible adhesive a mucoadhesive, erodible multi-layered device comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time of the device. The first layer preferably comprises a tooth-whitening agent, at least one water-soluble film-forming polymer in combination with at least one mucoadhesive polymer; and said second, water-erodible non-adhesive backing layer comprises a precast film containing at least one of hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, polyethylene glycol, polyethylene oxide, and ethylene oxide-propylene oxide co-polymer, said backing layer being coated with at least one hydrophobic polymer, alone or in combination with at least one hydrophilic polymer, such that the backing layer is bioerodible.
- An important aspect of the present invention is a mucoadhesive, erodible multi-layered device comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time of the device. The first layer comprises a tooth-whitening agent (most preferably carbamide peroxide), at least one water-soluble film-forming polymer in combination with at least one mucoadhesive polymer. Said second, water-erodible non-adhesive backing layer comprises a precast film containing at least one of hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, polyethylene glycol, polyethylene oxide, and ethylene oxide-propylene oxide co-polymer. This backing layer is coated with at least one hydrophobic polymer, alone or in combination with at least one hydrophilic polymer, such that the backing layer is bioerodible. The second water-erodible non-adhesive backing layer acts as a casting and support surface on which the adhesive layer is prepared. It preferably, and comprises a premade film of hydroxypropyl methyl cellulose in combination with a coating consisting of at least one hydrophobic polymer selected from the family of quaternary ammonium acrylate/methacrylate co-polymers, (Eudragit RS) ethyl cellulose and methyl cellulose, alone or in combination with at least one hydrophilic polymer, selected from the group consisting of polyvinyl pyrrolidone, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and polyvinyl alcohol.
- In the present invention, a unique, erodible, layered device that adheres to tooth enamel surfaces is provided. The device is most applicable for the cosmetic treatment of stained teeth, by delivering a whitening agent or combination of agents thereof for a controlled period of time. The device can also be used for the delivery of fluoride ions and phosphates for the preventative treatment of caries and tartar accumulation, respectively.
- The device initially adheres to a moist tooth surface due to the hydration and partial solubilization of the water soluble polymer layer. The whitening agent that is dispersed throughout this polymeric layer is then activated as it comes in contact with saliva and is released to the underlying surface. The erosion rate of the device is controlled by the coated backing layer, which affects the amount of time the whitening agent remains in contact with the enamel surface. The main purpose of the backing layer is to slow down the dissolution of the water-soluble polymeric layer containing a whitening agent, and therefore maximizing the direct contact time and unidirectional delivery to the tooth surface. The composition of the backing layer is easily adjusted to provide variable erosion rates from one half hour to several hours. The layered device is essentially totally erodible, and therefore does not require removal after the appropriate treatment time.
- The Residence Time as defined above is difficult to quantitatively ascertain. One visual method is to apply the layered device to the teeth surface and periodically observe the covered surface using a mirror and assess approximately how much residue remains on the surface. Typically, as the backing layer erodes away at a predetermined rate, the adhesive swells and starts to dissolve and fall off the teeth surface. The actual residence time on each surface is controlled primarily by the flow of saliva to the surface and any friction created by interaction with the internal surface of the lips.
- The polymeric coating layer that adheres to the tooth enamel is composed of one or more adhesive polymers, an appropriate whitening agent and a plasticizer. This coating may also contain an antioxidant, a preservative and a taste-masking flavor.
- The adhesive polymers can be any water soluble, FDA approved polymer for oral applications that sticks to an enamel surface when in contact with a moist tooth surface. The adhesive polymers may comprise hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxyethylmethyl cellulose, sodium carboxymethyl cellulose, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, polyacrylic acid, polyethylene oxide, alone or in combination thereof. The preferred adhesive polymers are hydroxyethyl cellulose and polyvinyl pyrrolidone since they exhibit rapid and effective adhesion to enamel when in contact with a moist tooth surface.
- The molecular weight of the adhesive polymer is also important, since it must be large enough so that an integral film can form, but not so large that immediate interfacial solubilization and adhesion to the enamel surface is impaired. Typical average molecular weights range between 50,000 and 1,500,000 Daltons, and preferably between 50,000 and 500,000.
- The whitening agents suitable for the practice of the present invention include peroxides, metal chlorites, perborates, percarbonates, peroxyacids, persulfates, alone or in combination thereof. Suitable peroxide compounds include hydrogen peroxide, carbamide peroxide, calcium peroxide, and mixtures thereof. The preferred peroxide is carbamide peroxide. Suitable metal chlorites include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite, and potassium chlorite. The preferred chlorite is sodium chlorite. A preferred percarbonate is sodium percarbonate, and the preferred persulfates are oxones.
- The rate at which the whitening agent is solubilized and subsequently released to a tooth surface is controlled by varying the film thickness, polymer properties such as structure and molecular weight, type and properties of whitening agent and the concentration of the whitening agent. The concentration of the whitening agent typically varies from about 0.1% to about 30% by weight of the total layered device, and preferably from about 0.5% to about 20% by weight.
- A plasticizer useful for purposes of the present invention is selected from glycols such as propylene glycol, polyethylene glycol, polyhydric alcohols such as glycerin and sorbitol and glycerol esters such as glycerol triacetate. The plasticizer comprises about 0.2% to about 30% by weight of the film of the present invention and preferably about 0.5% to about 10% by weight.
- Glycerin and propylene glycol are the preferred plasticizers for use in the present invention as well as polyethylene glycol. The preferred molecular weights for polyethylene glycol are in the range of 200-600 Daltons.
- A colorant or opacifier can be incorporated in the adhesive layer or any of the layers of this device for use as an appearance enhancer. The colorant or opacifier comprises about 0.01% to about 10% by weight of the film of the present invention and preferably about 0.03% to about 1% by weight. Colors and opacifiers may also be used to help distinguish the non-adhesive backing layer from the enamel adhering layer. Some opacifiers include titanium dioxide, zinc oxide, zirconium silicate and others.
- In addition to the incorporation of whitening agents, a plasticizer, and colorants, there may also be included in the adhesive film matrix a minor amount, e.g., 0.01 to 2% by weight, of ingredients such as preservatives, antioxidants, and flavors.
- The backing layer solution is composed of a mixture of a hydrophobic polymer, such as ethyl cellulose, methyl cellulose, propyl cellulose or other related polymers and copolymers, anionic, cationic and neutral polymers and copolymers of methyl methacrylate under the trade name EUDRAGIT®, and a water soluble polymer such as polyvinyl pyrrolidone, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol or any other water soluble polymer that can be completely commixed with the hydrophobic polymer(s), dissolved in ethanol or other suitable organic solvent. The ratio of the hydrophobic to the hydrophilic polymer is adjusted to increase or decrease the desired residence time that the device remains on the teeth before complete erosion. The ratio of hydrophobic to hydrophilic polymer ranges from 0.5:1 to 10:1 by weight, and more preferably 1.5:1 to 3:1 by weight.
- The backing layer solution may also contain a plasticizing agent, such as propylene glycol, polyethylene glycol, or glycerin, in a small amount, 0.1 to 2.0% by weight, in order to improve the flexibility and conformability of the resultant layered film and to adjust the erosion rate of the device. Colors and opacifiers may also be added to help distinguish the non-adhesive backing layer from the enamel adhering layer.
- Once dissolved, these solutions (adhesive and backing) are cast and processed into a thin film by techniques known in the art, such as by film dipping, film coating, film casting, spin coating, or spray drying. These films are produced on an appropriate support at the desired thickness and dried using an oven. The primary support can be a polymer-coated paper, Mylar or any other appropriate non-deformable and impervious surface. The preferable primary support is coated paper. The primary support's casting surface must hold the film dimensionally stable during the coating and drying processes, but allow the resulting composite film to release when desired. The actual casting surface for these solutions may be the primary support or another layer of the device being produced, such as the precast film layer or a freshly cast adhesive or backing layer. The amount of coating solutions applied, using a suitable doctor blade or lab coater apparatus, ranges between 0.01 to 1.5 mm, and most preferably between 0.05 and 0.4 mm for the backing layer and between 0.8 and 1.3 mm for the adhesive layer. The amount of solids present in the coating solutions, the resulting solution viscosity and coating thickness applied determine the amount of coating film to be deposited on the casting surface.
- The final layered device will consist of an adhesive layer and a hydrophobic layer with or without a precast hydroxypropylmethyl cellulose (HPMC) film in-between. A precast water soluble film between the adhesive and backing layers will typically provide a longer residence time on the teeth. Several methods of forming this device are now provided herein.
- In one embodiment, the adhesive layer is formed on an appropriate primary support. In a separate operation, the backing layer is formed on a water soluble, polymeric precast film of HPMC. The two films are then laminated, with the hydrophobic layer either on the outside or in the middle of the final composite film, using an appropriate binding solution such as polyvinylpyrrolidone dissolved in a water/ethanol mixture. This multi-layered film can be either peeled away from the primary support and cut into the desired shape or cut with the primary support still attached.
- In another embodiment, the backing layer is formed on an appropriate primary support. A precast film of HPMC is then laminated to the backing layer using binding solution consisting of polyvinylpyrrolidone dissolved in a water/ethanol mixture. Then a distinct binding layer, typically composed of polyvinylpyrrolidone is formed on top of the HPMC precast film. Finally, the adhesive layer is formed on top of the binding layer. This resulting multi-layer film is then further processed as outlined above.
- In a preferred embodiment, the adhesive layer is formed on an appropriate primary support by the casting methods previously described. The backing layer is then formed directly on top of the adhesive layer. This two-layer film is then further processed as outlined above.
- In another preferred embodiment, the backing layer is formed on an appropriate primary support by the casting methods previously described The adhesive layer is then formed directly on top of the backing layer and the resulting bilayered product is further processed as outlined above.
- The thicknesses of each layer will affect the residence time of the device. The hydrophobic layer composition and thickness are the most important parameters in controlling the residence time. However, inclusion of the water soluble, polymeric precast film as one of the layers of the device will also increase the residence time, since the overall thickness of the device is increased.
- The total thickness of the device is also an important consideration in regards to user acceptance. A very thick device becomes more noticeable with respect to “mouth feel”, and may cause the user to discontinue its use prematurely, thus compromising efficacy.
- The total thickness of the device will also affect its ability to conform and adhere to teeth in an efficient manner. Typically, thin films are preferred since they can be easily applied and bent around the teeth, minimizing the amount of unattached area in the form of edges and comers that could cause the film to be accidentally pulled off the teeth. However, if the film is too thin, it will begin to lose tensile strength and rip during its application.
- With respect to the individual layers of the composite film, the thickness of the adhesive layer is between 50μ and 300μ, and more preferably between 60μ and 140μ. The thickness of the backing layer is between 50μ and 300μ, and more preferably between 60μ and 100μ. The thickness of the precast layer if used to produce a multilayered device is between 25μ and 200μ, and more preferably between 50μ and 100μ. The overall thickness of the device is between 75μ and 500μ, and more preferably between 125μ and 300μ.
- A 180.0 gram batch of placebo adhesive solution was prepared using 10.0 grams hydroxyethyl cellulose (Natrosol 250L NF; Hercules), 10.0 grams polyvinyl pyrrolidone (PVP; Povidone P-1416; Spectrum), 0.65 grams sodium benzoate (Spectrum), 0.65 grams propylene glycol (Spectrum), and 158.7 grams deionized and 0.22μ-filtered water. This solution was used in Example 11 below.
- A 29.87 gram batch of active adhesive solution was prepared using 4.37 grams hydroxyethyl cellulose (Natrosol 250L NF; Hercules), 1.80 grams PVP (Povidone P-1416; Spectrum), 0.09 grams sodium benzoate (Spectrum), 0.09 grams propylene glycol (Spectrum), 2.70 grams carbamide peroxide (Spectrum), and 20.82 grams deionized and 0.22μ-filtered water. This solution was used in Examples 12 and 13 below.
- A 25.94 gram batch of active adhesive solution was prepared using 3.51 grams hydroxyethyl cellulose (Natrosol 250L NF; Hercules), 1.66 grams PVP (Povidone P-1416; Spectrum), 0.08 grams sodium benzoate (Spectrum), 0.08 grams propylene glycol (Spectrum), 2.49 grams carbamide peroxide (Spectrum), and 18.12 grams deionized and 0.22μ-filtered water. This solution was used in Examples 14 and 15 below.
- A 46.84 gram batch of active adhesive solution was prepared using 2.70 grams hydroxyethyl cellulose (Natrosol 250L NF; Hercules), 1.35 grams PVP (Povidone P-1416; Spectrum), 0.15 grams sodium benzoate (Spectrum), 0.15 grams propylene glycol (Spectrum), 2.70 grams carbamide peroxide (Spectrum), 1.95 grams sodium alginate, and 37.84 grams deionized and 0.22μ-filtered water. This solution was used in Examples 16 and 17 below.
- A 19.0 gm batch of backing solution was prepared using 2.0 grams of ethyl cellulose (Ethocel Premium Std 7; Dow Chemical), 1.0 grams of HPMC (Methocel E5 Prem LV; Dow Chemical), 1.0 gram Adams Extract Red Food Color, and 15.0 grams ethanol (190 proof; USP; Spectrum). This backing solution was used in Examples 11, 15, and 18 below.
- A 16.5 gram batch of backing solution was prepared using 1.1 grams of ethyl cellulose, 1.1 grams of HPMC, 0.9 grams Adams Extract Red Food Color, and 13.4 grams ethanol (190 proof, USP; Spectrum). This backing solution was used to make Examples 16 and 17 below.
- A 19.8 gram batch of backing solution was prepared using 2.2 grams of ethyl cellulose, 1.1 grams of HPMC, and 16.5 grams ethanol (190 proof, USP; Spectrum). This backing solution was used to make Examples 12, 13, 19, and 20 below.
- A 25.2 gram batch of backing solution was prepared using 1.8 grams of ethyl cellulose, 1.8 grams of HPMC, and 21.6 grams ethanol (190 proof, USP; Spectrum). This backing solution was used to make Examples 21 and 22 below.
- A 52.7 gram batch of laminating solution was prepared using 6.32 grams PVP (P1416; Spectrum), 23.19 grams ethanol (190 proof, USP; Spectrum), and 23.19 grams deionized and 0.22μ-filtered water.
- The precast HPMC film used in several embodiments of this device was typically a 100μ thick sheet called EM1100 from Polymer Films. In some embodiments, it was stretched on a paper-and-foil frame of a Werner Mathis AG Lab Coater, type LTF, and a backing solution selected from Examples 5-8 was poured on top and doctor-bladed at a 0.25 mm setting, then dried in the oven section of the Lab Coater.
- A composite device was made by doctor-blading the adhesive solution of Example 1 into a film using the Lab Coater. The casting was performed on a polymer-coated paper from Fortifiber, which was put on the paper and foil frame of the Lab Coater, with a doctor blade setting of 1.76 mm. The film was automatically dried in the oven portion of the Lab Coater, and a smooth, integral layer of deposited, adhesive polymer resulted. Then, separately, a layer of backing solution from Example 5 was doctor-bladed on top of the precast HPMC film (Example 10) using a 0.25 mm setting. The two films were then laminated together using the laminating solution described in Example 9 and pressure from a roller, followed by drying in the Lab Coater oven. The film was cut either before or after removal from the coated paper and upon application to a moist tooth surface, the film stuck well.
- A composite device was made as in Example 11, except using the adhesive of Example 2, with doctor-blade setting of 1.00 mm, and the backing solution of Example 7. After cutting and removal from the casting coated paper, the resulting film also stuck well to teeth.
- Another composite device was made by putting a backing layer of 2:1 ethyl cellulose to HPMC as described in Example 7 on polymer-coated paper (from Fortifiber) and then putting a layer of whitening adhesive (Example 2) on top of it. The backing layer was doctor-bladed at a 0.43 mm setting and the adhesive was doctor-bladed at a setting of 1.30 mm. This film after removal from the paper and cutting, stuck immediately and firmly to teeth, conformed extremely well, and eroded away without notice.
- A composite device composed of only an adhesive layer was made using the process outlined in Example 11, except the adhesive of Example 3 was used and with a doctor blade setting of 1.30 mm. A test was done to determine the whitening efficacy of this adhesive layer alone as compared to the competitive product Crest Whitestrips. Both products were dampened and pressed onto a coffee-stained white cup. They were removed after 16 hours. The amount of whitening was compared and ranked by eight individuals who did not know which device did which whitening. The results shown below indicate that the adhesive layer containing a whitening agent is as effective if not better than one competitive product.
- Adhesive only: 5 firsts, 1 tie, and 2 seconds; relative average score=1.38
- Crest White Strip: 2 first, 1 tie, and 5 seconds; relative average score=1.75
- A composite device was made by putting a layer of active adhesive from Example 3 on a polymer-coated paper (Fortifiber) and then putting a layer of backing solution from Example 5 on top of it. The adhesive was doctor-bladed at settings of 1.30 mm. The backing layer was spread thinly onto the surface of the dried adhesive film using a spatula and then dried. This resulting film after removal from the coated paper stuck well to the teeth.
- A composite device was made as in Example 11, except using the adhesive of Example 4 and with a doctor blade setting of 1.30 mm and the backing solution of Example 6 with a doctor blade setting of 0.25 mm. A strip of this film after removal from the surface of the coated paper and cutting, lasted about 1½ hours on the front teeth.
- A composite device was made as in Example 15, except using the adhesive of Example 4 and the backing solution of Example 6. A strip of this film after removal from the surface of the coated paper and cutting, lasted about 1 hour on the front teeth.
- A composite device was made as in Example 11, except using the adhesive of Example 3 without the tooth whitening agent, carbamide peroxide, and doctor blade settings of 1.30 mm. After processing, this placebo film visually seemed similar to the active films and upon removal from the coated paper and cutting, stuck comparably to the teeth.
- A composite device was made as in Example 11, except using the adhesive of Example 4, a doctor blade setting of 1.30 mm, and the backing solution of Example 7.
- A composite device was made as in Example 15, except using the adhesive of Example 4, with a doctor blade setting of 1.30 mm, and the backing solution of Example 7. The resulting film after removal from the coated paper and cutting, lasted more than ½ hour on the front teeth.
- A composite device was made as in Example 11, except using the adhesive of Example 4, with doctor blade setting of 1.30 mm, and the backing solution of Example 8. The resulting film after removal from the coated paper and cutting, lasted about 1½ hours on the front teeth.
- A composite device was made as in Example 15, except using the adhesive of Example 4, with doctor blade setting of 1.30 mm, and the backing solution of Example 8. The resulting film, after removal from the coated paper and cutting, lasted about 1 hour on the front teeth.
- Those skilled in the art will recognize that, while specific embodiments and examples have been described, various modifications and changes may be made without departing from the scope and spirit of this invention.
Claims (31)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/444,512 US20040062724A1 (en) | 2001-08-16 | 2003-05-23 | Erodible film for treating the surfaces of teeth |
US11/192,524 US20060073174A1 (en) | 2001-08-16 | 2005-07-29 | Adherent and erodible film to treat a moist surface of a body tissue |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/931,319 US6585997B2 (en) | 2001-08-16 | 2001-08-16 | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
US10/444,512 US20040062724A1 (en) | 2001-08-16 | 2003-05-23 | Erodible film for treating the surfaces of teeth |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/931,319 Continuation-In-Part US6585997B2 (en) | 2001-08-16 | 2001-08-16 | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/192,524 Continuation-In-Part US20060073174A1 (en) | 2001-08-16 | 2005-07-29 | Adherent and erodible film to treat a moist surface of a body tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040062724A1 true US20040062724A1 (en) | 2004-04-01 |
Family
ID=25460591
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/931,319 Expired - Lifetime US6585997B2 (en) | 2001-08-16 | 2001-08-16 | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
US10/444,512 Abandoned US20040062724A1 (en) | 2001-08-16 | 2003-05-23 | Erodible film for treating the surfaces of teeth |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/931,319 Expired - Lifetime US6585997B2 (en) | 2001-08-16 | 2001-08-16 | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
Country Status (16)
Country | Link |
---|---|
US (2) | US6585997B2 (en) |
EP (1) | EP1418889A2 (en) |
JP (2) | JP2005504763A (en) |
KR (1) | KR20040039290A (en) |
CN (2) | CN101849924A (en) |
AU (1) | AU2002326664B2 (en) |
CA (1) | CA2459692A1 (en) |
HU (1) | HUP0401281A3 (en) |
IL (2) | IL160419A0 (en) |
IS (1) | IS7155A (en) |
MX (1) | MXPA04001491A (en) |
NZ (1) | NZ531766A (en) |
PL (1) | PL373327A1 (en) |
RU (1) | RU2343903C2 (en) |
WO (1) | WO2003015748A2 (en) |
ZA (1) | ZA200402067B (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040265245A1 (en) * | 2003-05-27 | 2004-12-30 | Allred Peter M. | Substantially solid bleaching or treatment compositions in the form of inserts for dental trays, and kits comprising such inserts and trays |
US20050072369A1 (en) * | 2003-09-18 | 2005-04-07 | Goossen Theodorus Jozef | Submergible terrarium |
US20050081760A1 (en) * | 2003-07-01 | 2005-04-21 | Leng Lu H. | Table top |
US20050100515A1 (en) * | 2002-09-11 | 2005-05-12 | The Procter & Gamble Company | Tooth whitening products |
US20050196358A1 (en) * | 2004-03-03 | 2005-09-08 | Constantine Georgiades | Film products having controlled disintegration properties |
US20050196350A1 (en) * | 2004-03-03 | 2005-09-08 | Constantine Georgiades | Stabilized peroxide compositions |
US20050196354A1 (en) * | 2004-03-03 | 2005-09-08 | Andre Soshinsky | Film compositions |
WO2005102254A1 (en) * | 2004-04-08 | 2005-11-03 | The Procter & Gamble Company | Tooth whitening products |
WO2005110344A1 (en) | 2004-05-10 | 2005-11-24 | Colgate-Palmolive Company | Multilayer tooth whitening strips |
US20050276760A1 (en) * | 2004-06-09 | 2005-12-15 | Lornamead Brands, Inc. | Tooth for whitening products and methods of making the same |
WO2006013081A1 (en) * | 2004-08-02 | 2006-02-09 | Glaxo Group Limited | Novel composition for xerostomia |
US20070003495A1 (en) * | 1997-06-06 | 2007-01-04 | The Procter & Gamble Company | Methods for whitening teeth |
US20070140985A1 (en) * | 2005-12-21 | 2007-06-21 | Boyd Thomas J | Cleaning and/or Polishing Compositions and Methods of Use Thereof |
US20070190125A1 (en) * | 2004-03-03 | 2007-08-16 | Constantine Georgiades | Positioning feature for aiding use of film or strip product |
US20070218015A1 (en) * | 2003-11-03 | 2007-09-20 | Craig Hardy | Tooth-Whitening Composition |
US20070269519A1 (en) * | 2004-03-03 | 2007-11-22 | Constantine Georgiades | Whitening products |
US20080003248A1 (en) * | 2004-03-03 | 2008-01-03 | Constantine Georgiades | Whitening products |
US20080014224A1 (en) * | 2006-07-14 | 2008-01-17 | Boyd Thomas J | Methods of Making Compositions Comprising Films |
US20080286317A1 (en) * | 2004-10-13 | 2008-11-20 | Lts Lohmann Therapie-Systeme Ag | Self-Adhesive Film for Teeth |
WO2008157033A1 (en) * | 2007-06-20 | 2008-12-24 | Mcneil-Ppc, Inc | Products for whitening teeth |
USRE42126E1 (en) | 1999-07-02 | 2011-02-08 | The Procter & Gamble Company | Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip |
US8137658B2 (en) | 2005-06-28 | 2012-03-20 | Isp Investments Inc. | Tooth whitening compositions |
WO2012064319A1 (en) | 2010-11-08 | 2012-05-18 | Colgate-Palmolive Company | Oral compositions containing microaggregates |
WO2012082101A1 (en) | 2010-12-13 | 2012-06-21 | Colgate-Palmolive Company | Oral compositions and method for producing thereof |
WO2012082103A1 (en) | 2010-12-13 | 2012-06-21 | Colgate-Palmolive Company | Oral compositions and method for producing thereof |
WO2012082098A1 (en) | 2010-12-13 | 2012-06-21 | Colgate-Palmolive Company | Oral compositions and method for producing thereof |
WO2013002505A1 (en) * | 2011-06-27 | 2013-01-03 | 조선대학교 산학협력단 | Tape-type fluorine preparation using a biodegradable polymer material, and method for producing same |
RU2482836C1 (en) * | 2009-04-02 | 2013-05-27 | Колгейт-Палмолив Компани | Consumer products changing colour |
WO2013087623A2 (en) | 2011-12-12 | 2013-06-20 | Glaxo Group Limited | Novel composition |
US9554976B2 (en) | 2002-09-11 | 2017-01-31 | The Procter & Gamble Company | Tooth whitening product |
EP4385458A1 (en) | 2022-12-14 | 2024-06-19 | vVardis AG | Oral film with multiple regions for therapy of periodontal and dental diseases or disorders |
Families Citing this family (254)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19646392A1 (en) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery |
US7713297B2 (en) | 1998-04-11 | 2010-05-11 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
AU2002316053A1 (en) | 2001-05-01 | 2002-11-11 | A.V. Topchiev Institute Of Petrochemical Synthesis | Two-phase, water-absorbent bioadhesive composition |
US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
DE60233217D1 (en) | 2001-05-01 | 2009-09-17 | Corium Internat Inc | HYDROGEL COMPOSITIONS |
US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
AU2002345328A1 (en) | 2001-06-27 | 2003-03-03 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20060073174A1 (en) * | 2001-08-16 | 2006-04-06 | Access Pharmaceuticals, Inc. | Adherent and erodible film to treat a moist surface of a body tissue |
US20110092677A1 (en) * | 2001-08-30 | 2011-04-21 | Biorexis Technology, Inc. | Modified transferin-antibody fusion proteins |
US8425892B2 (en) * | 2001-10-29 | 2013-04-23 | Columbia Laboratories, Inc. | Extended, controlled-release pharmaceutical compositions using charged polymers |
US7201930B2 (en) * | 2001-11-05 | 2007-04-10 | Haley Jeffrey T | Licorice root extract oral patch for treating canker sores |
US20030099691A1 (en) * | 2001-11-16 | 2003-05-29 | Susan Lydzinski | Films containing starch |
US20030124178A1 (en) * | 2001-12-28 | 2003-07-03 | Haley Jeffrey T. | Soft, adherent, soluble oral patch |
US20030224090A1 (en) * | 2002-02-11 | 2003-12-04 | Edizone, Lc | Snacks of orally soluble edible films |
US8999372B2 (en) | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
US20040191302A1 (en) | 2003-03-28 | 2004-09-30 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US20040131662A1 (en) | 2003-11-12 | 2004-07-08 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
MXPA05005243A (en) * | 2002-11-14 | 2006-03-10 | Innozen Inc | Edible film for relief of cough or symptoms associated with pharyngitis. |
US9561182B2 (en) * | 2003-08-22 | 2017-02-07 | Cure Pharmaceutical Corporation | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals |
US6669929B1 (en) | 2002-12-30 | 2003-12-30 | Colgate Palmolive Company | Dentifrice containing functional film flakes |
IE20040202A1 (en) * | 2003-03-28 | 2004-10-06 | Sigmoid Biotechnologies Ltd | Solid oral dosage form containing seamless microcapsules |
AU2003283851A1 (en) * | 2003-04-30 | 2004-12-13 | Icure Pharmaceutical Corporation | Patch for tooth whitening |
US7276246B2 (en) * | 2003-05-09 | 2007-10-02 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
US7306812B2 (en) | 2003-05-09 | 2007-12-11 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
US7056118B2 (en) * | 2003-05-27 | 2006-06-06 | Ultradent Products, Inc. | Compositions and devices having a tray-like configuration for delivering a medicament and methods of manufacturing and using such compositions and devices |
US20040241151A1 (en) * | 2003-05-27 | 2004-12-02 | Sca Hygiene Products Ab | Polymer matrix with lactic acid producing bacteria |
WO2005009364A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
CA2533292C (en) | 2003-07-21 | 2013-12-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
US8313776B2 (en) | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
EP1653925A1 (en) | 2003-08-11 | 2006-05-10 | Advancis Pharmaceutical Corporation | Robust pellet |
US8062672B2 (en) | 2003-08-12 | 2011-11-22 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
EP1660056A4 (en) * | 2003-08-15 | 2008-12-17 | Arius Two Inc | BIODEGRADABLE ADHESIVE DRUG DELIVERY SYSTEM FOR MUCOUS MEMBRANES |
WO2005023184A2 (en) | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
AU2004273830B2 (en) | 2003-09-15 | 2011-03-24 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
KR20070007299A (en) | 2004-01-30 | 2007-01-15 | 코리움 인터네셔널, 인크. | Quick Melt Films for Delivery of Active Agents |
EP1744760B1 (en) * | 2004-04-22 | 2015-01-07 | AcuCort AB | Pharmaceutical compositions for acute glucocorticoid therapy |
US7666914B2 (en) * | 2004-06-03 | 2010-02-23 | Richlin David M | Topical preparation and method for transdermal delivery and localization of therapeutic agents |
SI1765292T1 (en) | 2004-06-12 | 2018-04-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
CA2572292A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
WO2006017807A2 (en) | 2004-08-05 | 2006-02-16 | Corium International, Inc. | Adhesive composition |
CA2518650A1 (en) * | 2004-09-10 | 2006-03-10 | Dimitrios Dimitrakoudis | Clostridium botulinum toxin formulation and method for reducing weight |
CA2581764A1 (en) * | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Minicapsule formulations |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
WO2006036982A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Drug delivery coating for use with a stent |
EP1812022B1 (en) | 2004-09-28 | 2014-01-15 | Atrium Medical Corporation | Stand-alone film and methods for making the same |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
AR051397A1 (en) * | 2004-10-21 | 2007-01-10 | Novartis Ag | PHARMACEUTICAL COMPOSITION |
JP5002462B2 (en) * | 2004-12-09 | 2012-08-15 | バイエル・アニマル・ヘルス・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Stabilization of glucocorticoid esters by acid. |
US20060134201A1 (en) * | 2004-12-16 | 2006-06-22 | Haley Jeffrey T | Collagen troches for treating mouth lesions |
GB2421431B (en) * | 2004-12-24 | 2007-10-10 | Aquasol Ltd | Dosing systems |
DE102005015128B4 (en) * | 2005-03-31 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Wafers containing steroid hormones |
US9023382B2 (en) * | 2005-06-08 | 2015-05-05 | Basf Corporation | Medicament carrier composition and method of forming a film therefrom |
US20060281775A1 (en) * | 2005-06-14 | 2006-12-14 | Applied Pharmacy Services, Inc. | Two-component pharmaceutical composition for the treatment of pain |
US8114914B2 (en) | 2005-06-17 | 2012-02-14 | Wisconsin Alumni Research Foundation | Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy |
US8252776B2 (en) * | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US8722650B1 (en) | 2005-06-24 | 2014-05-13 | Medicis Pharmaceutical Corporation | Extended-release minocycline dosage forms |
US20080242642A1 (en) | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
AU2006265707B2 (en) * | 2005-07-01 | 2012-06-14 | Kane Biotech Inc. | Antimicrobial compositions for inhibiting growth and proliferation of a microbial biofilm on medical devices |
US20070042027A1 (en) * | 2005-08-22 | 2007-02-22 | Haley Jeffrey T | Water soluble anesthetic in an oral patch of hydrophilic gums |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
AU2006304590A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
KR20070057660A (en) * | 2005-12-01 | 2007-06-07 | 롬 앤드 하아스 컴패니 | Aqueous Polymer Dispersion to Stabilize Actives |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
BRPI0619806A2 (en) * | 2005-12-13 | 2011-10-18 | Biodelivery Sciences Int Inc | abuse resistant transmucosal drug delivery device |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
ATE493118T1 (en) * | 2006-01-19 | 2011-01-15 | Dow Global Technologies Inc | BIOLOGICALLY EFFECTIVE COMPOSITION WITH ETHYLCELLULOSE |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US20070192183A1 (en) * | 2006-02-10 | 2007-08-16 | Tovin Monaco | System and architecture for providing retail buying options to consumer using customer data |
US20070192438A1 (en) * | 2006-02-10 | 2007-08-16 | Esmond Goei | System and method for on-demand delivery of media products |
US20070192182A1 (en) * | 2006-02-10 | 2007-08-16 | Tovin Monaco | Method of delivering coupons using customer data |
US20070190013A1 (en) * | 2006-02-13 | 2007-08-16 | Yeli Zhang | Film and film-forming compositions |
US8349120B2 (en) * | 2006-03-07 | 2013-01-08 | Ora Health Corporation | Multi-layer patch made on a sheet and enclosed in a blister |
US20070224235A1 (en) | 2006-03-24 | 2007-09-27 | Barron Tenney | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
CA2647801C (en) * | 2006-03-24 | 2015-04-14 | Auxilium Pharmaceuticals, Inc. | Process for the preparation of a hot-melt extruded laminate |
CA2647809C (en) | 2006-03-24 | 2016-08-16 | Auxilium Pharmaceuticals, Inc. | Stabilized compositions containing alkaline labile drugs |
US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US20070248655A1 (en) * | 2006-04-21 | 2007-10-25 | Haley Jeffrey T | Lenticular shaped protective mouth sore discs |
US20070248654A1 (en) * | 2006-04-21 | 2007-10-25 | Haley Jeffrey T | Protective mouth sore discs made with corn starch |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
US20070264487A1 (en) * | 2006-05-12 | 2007-11-15 | Dean Georgiades | Treated film strips |
CN1850059B (en) * | 2006-05-29 | 2010-05-12 | 王法平 | Amlexanox oral membrane, and its preparing method |
US20070289596A1 (en) * | 2006-06-14 | 2007-12-20 | Campbell Shannon E | Endotracheal cuff and technique for using the same |
WO2008035361A2 (en) * | 2006-06-14 | 2008-03-27 | Arrow Coated Products Ltd | Device for delivering active ingredients to humans, animals and plants |
US20070298087A1 (en) * | 2006-06-27 | 2007-12-27 | Biegajski James E | Two-phase mucoadhesive composition |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
EP2032091A2 (en) | 2006-06-29 | 2009-03-11 | Boston Scientific Limited | Medical devices with selective coating |
JP5448814B2 (en) | 2006-07-21 | 2014-03-19 | バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド | Transmucosal delivery device to enhance uptake |
CA2659761A1 (en) | 2006-08-02 | 2008-02-07 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
WO2008033711A2 (en) | 2006-09-14 | 2008-03-20 | Boston Scientific Limited | Medical devices with drug-eluting coating |
CA2663250A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprostheses and methods of making the same |
EP2399616A1 (en) | 2006-09-15 | 2011-12-28 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
EP2068782B1 (en) | 2006-09-15 | 2011-07-27 | Boston Scientific Limited | Bioerodible endoprostheses |
CA2663220A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
WO2008036548A2 (en) | 2006-09-18 | 2008-03-27 | Boston Scientific Limited | Endoprostheses |
EP2626091B1 (en) | 2006-11-06 | 2016-09-28 | Atrium Medical Corporation | Coated surgical mesh |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
US20080140106A1 (en) * | 2006-12-12 | 2008-06-12 | Kimberly-Clark Worldwide, Inc. | Enhanced cuff sealing for endotracheal tubes |
JP5355418B2 (en) | 2006-12-28 | 2013-11-27 | ボストン サイエンティフィック リミテッド | Bioerodible endoprosthesis and method for manufacturing the bioerodible endoprosthesis |
US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
US8070797B2 (en) | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
CN102942572A (en) * | 2007-03-29 | 2013-02-27 | 普罗热尼奇制药公司 | Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof |
CA2683415C (en) | 2007-04-04 | 2020-12-08 | Sigmoid Pharma Limited | An oral pharmaceutical composition |
US8067054B2 (en) | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
US20080260836A1 (en) * | 2007-04-18 | 2008-10-23 | Thomas James Boyd | Films Comprising a Plurality of Polymers |
EP2061587A1 (en) | 2007-04-26 | 2009-05-27 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
EP2063875A2 (en) * | 2007-05-01 | 2009-06-03 | Sigmoid Pharma Limited | Combination pharmaceutical compositions |
US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
EP2008651A1 (en) * | 2007-06-26 | 2008-12-31 | Drug Delivery Solutions Limited | A bioerodible patch |
US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US9284409B2 (en) | 2007-07-19 | 2016-03-15 | Boston Scientific Scimed, Inc. | Endoprosthesis having a non-fouling surface |
US7931683B2 (en) | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
WO2009018340A2 (en) | 2007-07-31 | 2009-02-05 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
WO2009020520A1 (en) | 2007-08-03 | 2009-02-12 | Boston Scientific Scimed, Inc. | Coating for medical device having increased surface area |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
CN101152163B (en) * | 2007-09-14 | 2010-05-26 | 李世荣 | Anti-cicatrix externally used pad pasting containing hormone medicament and method for preparing the same |
CN101152164B (en) * | 2007-09-14 | 2011-04-06 | 李世荣 | Anti-cicatrix externally used pad pasting containing anti-hypertrophy cell medicament and method for preparing the same |
US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7938855B2 (en) | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
PE20091084A1 (en) * | 2007-12-07 | 2009-07-23 | Schering Plough Healthcare | PHARMACEUTICAL FORMULATIONS OF PHENYLPHRINE AND COMPOSITIONS FOR TRANSMUCOSAL ABSORPTION |
CN101229174B (en) * | 2008-01-25 | 2010-12-15 | 广东一品红药业有限公司 | Antianaphylaxis compound containing epinastine hydrochloride |
EP2271380B1 (en) | 2008-04-22 | 2013-03-20 | Boston Scientific Scimed, Inc. | Medical devices having a coating of inorganic material |
US8932346B2 (en) | 2008-04-24 | 2015-01-13 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US20090304776A1 (en) * | 2008-06-06 | 2009-12-10 | Totada Shantha | Transmucosal delivery of therapeutic agents and methods of use thereof |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8449603B2 (en) | 2008-06-18 | 2013-05-28 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
AU2009271271A1 (en) * | 2008-06-23 | 2010-01-21 | Biodelivery Sciences International, Inc. | Multidirectional mucosal delivery devices and methods of use |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
WO2010017310A1 (en) | 2008-08-06 | 2010-02-11 | Medicis Pharmaceutical Corporation | Method for the treatment of acne and certain dosage forms thereof |
US20110092493A1 (en) * | 2008-09-24 | 2011-04-21 | Clark Levi | Dose-controlled transdermal promethazine compositions and methods of use |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
EP2387394B1 (en) | 2009-01-14 | 2018-05-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
EP2403546A2 (en) | 2009-03-02 | 2012-01-11 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
EP2432455B1 (en) | 2009-05-18 | 2014-11-12 | Sigmoid Pharma Limited | Composition comprising oil drops |
US9017718B2 (en) * | 2009-05-21 | 2015-04-28 | Bionex Pharmaceuticals Llc | Dual and single layer dosage forms |
US8778278B2 (en) | 2009-07-15 | 2014-07-15 | General Electric Company | Non bio-adhesive polymer coating composition, articles and devices thereof |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
BR112012002963A2 (en) | 2009-08-12 | 2017-10-24 | Sigmoid Pharma Ltd | immunomodulatory compositions comprising a polymer matrix and an oil phase |
US20110037455A1 (en) * | 2009-08-17 | 2011-02-17 | Oren Navot | System for measuring electrical power |
US9549842B2 (en) | 2011-02-04 | 2017-01-24 | Joseph E. Kovarik | Buccal bioadhesive strip and method of treating snoring and sleep apnea |
US8701671B2 (en) | 2011-02-04 | 2014-04-22 | Joseph E. Kovarik | Non-surgical method and system for reducing snoring |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
TWI435733B (en) | 2010-01-29 | 2014-05-01 | Colgate Palmolive Co | Oral care formulation for bad breath control |
CN105963279A (en) | 2010-01-29 | 2016-09-28 | 高露洁-棕榄公司 | Dental strip for administration of oral treatment |
US20110195042A1 (en) * | 2010-02-10 | 2011-08-11 | Thomas Edward Huetter | Compositions, Methods and Kits Useful for Treating a Respiratory Symptom |
CA2792523C (en) * | 2010-03-09 | 2018-01-09 | Alkermes Pharma Ireland Limited | Alcohol resistant enteric pharmaceutical compositions |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US9572773B2 (en) * | 2010-04-26 | 2017-02-21 | Novartis A.G. | Layered drug delivery device |
US20110268809A1 (en) | 2010-04-28 | 2011-11-03 | Paul Andrew Brinkley | Nicotine-Containing Pharmaceutical Compositions |
US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
WO2011139228A1 (en) * | 2010-05-07 | 2011-11-10 | Empire Technology Development Llc | Nano scale collagen particles and membranes |
RU2013103829A (en) | 2010-06-30 | 2014-08-10 | Колгейт-Палмолив Компани | MULTI-LAYERED FILMS FOR DELIVERY OF TASTE-AROMATIC ADDITIVES |
JP2013529682A (en) * | 2010-06-30 | 2013-07-22 | コルゲート・パーモリブ・カンパニー | Flavor release from multilayer films during brushing |
US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
WO2012092594A2 (en) * | 2010-12-30 | 2012-07-05 | Harish Ziv M D | Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
SI2686017T1 (en) | 2011-03-14 | 2019-11-29 | Drug Delivery Solutions Ltd | An ophthalmic composition |
US9561241B1 (en) | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
EP2594257A1 (en) * | 2011-11-17 | 2013-05-22 | Labtec GmbH | Orodispersible films for the manufacturing of individualised medicine or for large scale production |
WO2013023775A1 (en) * | 2011-08-12 | 2013-02-21 | Labtec Gmbh | Orodispersible films for the manufacturing of individualised medicine or for large scale production |
US9629392B2 (en) | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
US9474303B2 (en) | 2011-09-22 | 2016-10-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9084439B2 (en) | 2011-09-22 | 2015-07-21 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
WO2013110340A1 (en) * | 2012-01-27 | 2013-08-01 | Beta Pharma S.A. | Edible slow dissolving film for treating oral ulcerations |
US9763928B2 (en) | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
ES2634993T3 (en) | 2012-03-30 | 2017-10-02 | Nuformix Limited | Tranilast compositions and co-crystals |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
US20140255452A1 (en) | 2013-03-11 | 2014-09-11 | Niconovum Usa, Inc. | Method and apparatus for differentiating oral pouch products |
CN105209084B (en) | 2013-03-13 | 2018-07-03 | 艾利丹尼森公司 | Improved bond properties |
US11931227B2 (en) | 2013-03-15 | 2024-03-19 | Cook Medical Technologies Llc | Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding |
US20140271787A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Continuous single layer film structure including discrete domains |
ES2835258T3 (en) * | 2013-07-31 | 2021-06-22 | Bluepharma Ind Farmaceutica S A | Oral dispersible films |
CN105636616A (en) * | 2013-08-08 | 2016-06-01 | 波士顿科学国际有限公司 | Dissolvable or degradable adhesive polymer to prevent stent migration |
WO2015056196A1 (en) * | 2013-10-16 | 2015-04-23 | Orahealth Corporation | Treating mucosal lesions with hyaluronan delivered from an adhering troche |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US12246043B2 (en) | 2013-12-20 | 2025-03-11 | Seed Health, Inc. | Topical application to treat acne vulgaris |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
EP3086768B1 (en) | 2013-12-23 | 2019-02-20 | Colgate-Palmolive Company | Tooth whitening oral care product |
EP3086772A1 (en) * | 2013-12-23 | 2016-11-02 | Colgate-Palmolive Company | Film compositions for oral use |
EP2889030A1 (en) | 2013-12-30 | 2015-07-01 | Uluru Inc. | Controlling the erosion rates of mucoadhesive devices that deliver actives and other compounds and providing increased and variable therapeutic blood levels |
US20160354509A1 (en) * | 2014-02-10 | 2016-12-08 | The Johns Hopkins University | Devices for and methods of treatment of metabolic syndromes |
EP3106152B1 (en) * | 2014-02-12 | 2021-02-17 | Sawai Pharmaceutical Co., Ltd. | Orally disintegrating tablet coated with film |
CN104845549B (en) * | 2014-02-18 | 2019-07-12 | 财团法人工业技术研究院 | Wood adhesive, wood adhesion method using same and wood joint structure |
US9970303B2 (en) | 2014-05-13 | 2018-05-15 | Entrotech, Inc. | Erosion protection sleeve |
EP3154513B1 (en) * | 2014-06-10 | 2019-11-20 | Afyx Therapeutics A/S | Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa |
RU2700200C2 (en) | 2014-07-31 | 2019-09-13 | Джонсон энд Джонсон Консьюмер Инк. | Article and method for holding menstrual fluid within vagina |
US11623008B2 (en) * | 2014-08-20 | 2023-04-11 | Professional Compounding Centers Of America | Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan |
EA036036B1 (en) | 2014-11-07 | 2020-09-16 | Сигмойд Фарма Лимитед | Compositions comprising cyclosporin |
US20160144528A1 (en) | 2014-11-25 | 2016-05-26 | Biodelivery Sciences International, Inc. | Patch devices, methods and apparatus for forming, and testing pharmaceutical agent delivery patch devices |
EP3331499A4 (en) | 2015-08-06 | 2019-04-10 | The Johns Hopkins University | COMPOSITION AND METHOD OF TREATING METABOLIC DISORDERS |
TWI564356B (en) | 2015-09-18 | 2017-01-01 | 財團法人工業技術研究院 | Wood adhesive |
WO2017085262A1 (en) * | 2015-11-19 | 2017-05-26 | Dermtreat Aps | A pharmaceutical film composition having improved residence time on the application site |
US20170165252A1 (en) | 2015-12-10 | 2017-06-15 | Niconovum Usa Inc. | Protein-enriched therapeutic composition |
CA3010568C (en) * | 2016-01-27 | 2023-10-17 | Instar Technologies A.S. | Oromucosal nanofiber carriers for therapeutic treatment |
WO2017131691A1 (en) | 2016-01-28 | 2017-08-03 | Kimberly-Clark Worldwide, Inc. | Anti-adherent composition against dna viruses and method of inhibiting the adherence of dna viruses to a surface |
WO2017131686A1 (en) * | 2016-01-28 | 2017-08-03 | Kimberly-Clark Worldwide, Inc. | Adherent composition for rna viruses and method of removing rna viruses from a surface |
CN109310646A (en) | 2016-05-05 | 2019-02-05 | 阿奎斯蒂弗医疗股份有限公司 | Enhance the adrenaline composition of delivering |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
GB2565511B (en) | 2016-05-26 | 2022-04-13 | Kimberly Clark Co | Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
CN107865868B (en) | 2016-09-27 | 2020-04-10 | 上海微创医疗器械(集团)有限公司 | New application of amlexanox |
KR102595001B1 (en) | 2017-01-23 | 2023-10-26 | 에이에프와이엑스 테라퓨틱스 에스에이 | Method for producing electrospun fibers with high content of bioadhesive substances |
WO2018133909A1 (en) | 2017-01-23 | 2018-07-26 | Dermtreat Aps | Method for fabrication of a two-layered product based on electrospun fibres |
RU2699808C2 (en) * | 2017-12-05 | 2019-09-11 | Общество с ограниченной ответственностью "Эндокринные технологии" | Biodegradable system of transmucosal delivery of drotaverin |
EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
BR112020025604A2 (en) | 2018-06-15 | 2021-03-23 | R.J. Reynolds Tobacco Company | nicotine purification |
US11291654B2 (en) * | 2018-09-13 | 2022-04-05 | Syneurx International (Taiwan) Corp. | Formulations of cycloserine compounds and applications thereof |
CN109953984A (en) * | 2019-03-01 | 2019-07-02 | 哈尔滨医科大学 | A kind of compound tetracaine hydrochloride film and preparation method thereof |
TWI829888B (en) * | 2019-03-14 | 2024-01-21 | 瑞士商意梭凱普公司 | Pharmaceutical dosage form for application to mucous membranes and methods for producing same |
KR102234482B1 (en) * | 2019-05-14 | 2021-03-31 | 조선대학교산학협력단 | fluorine agent of dual film type using polymers with differential dissolution characteristics and manufacturing method thereof |
RU2729659C1 (en) * | 2019-05-29 | 2020-08-11 | Общество с ограниченной ответственностью "Эндокринные технологии" | Dosage form for releasing drotaverine in oral cavity |
CN113134085A (en) * | 2020-01-17 | 2021-07-20 | 四川大学华西第二医院 | Medicine for treating white lesions of vulva |
CN113181416B (en) * | 2021-04-26 | 2022-04-05 | 苏州和塑美科技有限公司 | Self-adhesive nanofiber antibacterial dressing easy to transfer and preparation method thereof |
CN114848612A (en) * | 2022-04-28 | 2022-08-05 | 青岛博益特生物材料股份有限公司 | Sheet material film coating process and film coated sheet material produced by same |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513243A (en) * | 1983-06-08 | 1985-04-23 | Westinghouse Electric Corp. | Core form transformer for selective cancellation of subsynchronous resonance |
US4713243A (en) * | 1986-06-16 | 1987-12-15 | Johnson & Johnson Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
US5437857A (en) * | 1989-05-24 | 1995-08-01 | American Dental Association Health Foundation | Methods and compositions for mineralizing and fluoridating calcified tissues |
US6056930A (en) * | 1989-05-24 | 2000-05-02 | American Dental Association Health Foundation | Methods and compositions for mineralizing and fluoridating calcified tissues |
US6419906B1 (en) * | 2001-03-12 | 2002-07-16 | Colgate Palmolive Company | Strip for whitening tooth surfaces |
US20030133884A1 (en) * | 2000-03-17 | 2003-07-17 | Sug-Youn Chang | Patches for teeth whitening |
US6649147B1 (en) * | 1999-07-02 | 2003-11-18 | The Procter & Gamble Company | Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip |
US6682721B2 (en) * | 2000-03-17 | 2004-01-27 | Lg Household & Healthcare Ltd. | Patches for teeth whitening |
US6946142B2 (en) * | 2001-06-23 | 2005-09-20 | Lg Household & Healthcare Ltd. | Multi-layer patches for teeth whitening |
US20060073174A1 (en) * | 2001-08-16 | 2006-04-06 | Access Pharmaceuticals, Inc. | Adherent and erodible film to treat a moist surface of a body tissue |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
US3948254A (en) | 1971-11-08 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
GB1593097A (en) | 1978-05-26 | 1981-07-15 | Fisons Ltd | Pharmaceutical compositions containing a bischromone |
JPS5562012A (en) | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
GB2042888B (en) | 1979-03-05 | 1983-09-28 | Teijin Ltd | Preparation for administration to the mucosa of the oral or nasal cavity |
US4286592A (en) | 1980-02-04 | 1981-09-01 | Alza Corporation | Therapeutic system for administering drugs to the skin |
JPS5758615A (en) | 1980-09-26 | 1982-04-08 | Nippon Soda Co Ltd | Film agnent and its preparation |
JPS5770816A (en) | 1980-10-17 | 1982-05-01 | Ono Pharmaceut Co Ltd | Multilayered film preparation of prostagladin of prolonged action |
JPS57110254A (en) | 1980-12-29 | 1982-07-09 | Teijin Ltd | Coating agent of injured membrane part of oral cavity |
CH653550A5 (en) * | 1981-10-20 | 1986-01-15 | Sandoz Ag | PHARMACEUTICAL COMPOSITION FOR DELAYED RELEASE OF A MEDICINE IN THE ORAL AREA. |
US4518721A (en) | 1982-03-26 | 1985-05-21 | Richardson-Vicks Inc. | Hydrophilic denture adhesive |
CA1208558A (en) | 1982-10-07 | 1986-07-29 | Kazuo Kigasawa | Soft buccal |
JPS59186913A (en) | 1983-04-08 | 1984-10-23 | Teikoku Seiyaku Kk | Base for oral mucosa patch |
WO1985002092A1 (en) | 1983-11-14 | 1985-05-23 | Bio-Mimetics Inc. | Bioadhesive compositions and methods of treatment therewith |
US5855908A (en) | 1984-05-01 | 1999-01-05 | University Of Utah Research Foundation | Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient |
US5783207A (en) | 1985-05-01 | 1998-07-21 | University Of Utah Research Foundation | Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine |
JPH0744940B2 (en) | 1986-12-24 | 1995-05-17 | ライオン株式会社 | Base material for oral application |
DE3714074A1 (en) | 1987-04-28 | 1988-11-10 | Hoechst Ag | BASIS FOR MUCUTINE AND PROSTHESISAL PASTE, METHOD FOR THEIR PRODUCTION AND PASTE BASED ON THIS BASE |
US4915948A (en) | 1987-08-31 | 1990-04-10 | Warner-Lambert Company | Tablets having improved bioadhesion to mucous membranes |
JP2635336B2 (en) * | 1987-09-30 | 1997-07-30 | 帝國製薬株式会社 | Sustained release oral preparation |
US5081157A (en) | 1988-05-02 | 1992-01-14 | Zila Pharmaceuticals, Inc. | Compositions and in situ methods for forming films on body tissue |
US5081158A (en) | 1988-05-02 | 1992-01-14 | Zila Pharmaceuticals, Inc. | Compositions and in situ methods for forming films on body tissue |
US5047244A (en) | 1988-06-03 | 1991-09-10 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
JP2656338B2 (en) | 1989-01-31 | 1997-09-24 | 日東電工株式会社 | Oral mucosa patch preparation |
US5139023A (en) | 1989-06-02 | 1992-08-18 | Theratech Inc. | Apparatus and method for noninvasive blood glucose monitoring |
ES2050096T3 (en) | 1989-10-31 | 1995-01-16 | Columbia Lab Inc | HUMIDIFYING COMPOSITION OF THE VAGINAL TISSUE. |
MC2204A1 (en) | 1989-10-31 | 1992-11-26 | Columbia Lab Inc | COMPOSITION AND METHOD FOR HUMIDIFYING TISSUE |
US6017521A (en) | 1989-10-31 | 2000-01-25 | Columbia Laboratories, Inc. | Use of polycarboxylic acid polymers to treat vaginal infections |
US5750134A (en) | 1989-11-03 | 1998-05-12 | Riker Laboratories, Inc. | Bioadhesive composition and patch |
US5750136A (en) | 1989-11-03 | 1998-05-12 | Riker Laboratories, Inc. | Bioadhesive composition and patch |
US5298258A (en) | 1989-12-28 | 1994-03-29 | Nitto Denko Corporation | Acrylic oily gel bioadhesive material and acrylic oily gel preparation |
US5192802A (en) | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
DK0641192T3 (en) | 1992-05-18 | 1998-03-02 | Minnesota Mining & Mfg | Transmucosal drug delivery device |
US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
US5578315A (en) | 1993-12-01 | 1996-11-26 | Rutgers, The State University Of New Jersey | Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity |
US5458879A (en) | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
US5639469A (en) | 1994-06-15 | 1997-06-17 | Minnesota Mining And Manufacturing Company | Transmucosal delivery system |
US6103226A (en) * | 1994-08-12 | 2000-08-15 | Arch Development Corporation | Genetically engineered cells that produce produce L. Dopa |
WO1996009829A1 (en) | 1994-09-27 | 1996-04-04 | Virotex Corporation | Improved topical carriers for mucosal applications |
US5667492A (en) | 1994-10-07 | 1997-09-16 | Columbia Laboratories, Inc. | Use and composition of an anti-sexually transmitted diseases formulation |
US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
US5888534A (en) | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
CA2184316A1 (en) | 1995-09-12 | 1997-03-13 | Wei-Chi Liao | Buccal delivery system for therapeutic agents |
IT1277663B1 (en) | 1995-09-28 | 1997-11-11 | Crinos Industria Farmaco | STABLE AQUEOUS SUSPENSIONS OF MESALAZINE FOR TOPICAL USE |
US5766620A (en) | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
US5849322A (en) | 1995-10-23 | 1998-12-15 | Theratech, Inc. | Compositions and methods for buccal delivery of pharmaceutical agents |
JP2791317B2 (en) * | 1995-12-26 | 1998-08-27 | 株式会社三和化学研究所 | Multilayer film preparation |
US5889028A (en) | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5955098A (en) | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
US5869082A (en) | 1996-04-12 | 1999-02-09 | Flemington Pharmaceutical Corp. | Buccal, non-polar spray for nitroglycerin |
ATE288255T1 (en) | 1996-04-12 | 2005-02-15 | Novadel Pharma Inc | POLAR BUCCAL SPRAY |
GB9610862D0 (en) * | 1996-05-23 | 1996-07-31 | Evans Brian K | Pharmaceutical products |
SE9602644D0 (en) | 1996-07-04 | 1996-07-04 | Astra Ab | New use |
US5861174A (en) | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
US5955097A (en) | 1996-10-18 | 1999-09-21 | Virotex Corporation | Pharmaceutical preparation applicable to mucosal surfaces and body tissues |
US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
FR2762513B1 (en) * | 1997-04-23 | 2003-08-22 | Permatec Pharma Ag | BIOADHESIVE TABLETS |
US5900230A (en) | 1997-08-18 | 1999-05-04 | Squigle, Inc. | Dental products to treat and prevent periodontal disease |
US5981499A (en) | 1998-02-20 | 1999-11-09 | Atlantic Biomed Corporation | Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa |
US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
PT1079813E (en) | 1998-04-29 | 2005-05-31 | Virotex Corp | PHARMACEUTICAL CARRIER TRANSPORTATION DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOUS SURFACES |
GB9812426D0 (en) | 1998-06-10 | 1998-08-05 | Reckitt & Colmann Prod Ltd | Improvements in or relating to organic compositions |
DK1135112T3 (en) * | 1998-11-27 | 2005-02-14 | Kanji Takada | Oral formulation for gastrointestinal drug administration |
US6284262B1 (en) | 1999-01-26 | 2001-09-04 | Virgil A. Place | Compact dosage unit for buccal administration of a pharmacologically active agent |
US6117446A (en) | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
EP2275133A1 (en) | 1999-02-26 | 2011-01-19 | Novartis Vaccines and Diagnostics, Inc. | Use of bioadhesives and adjuvants for the mucosal delivery of antigens |
US6375963B1 (en) * | 1999-06-16 | 2002-04-23 | Michael A. Repka | Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof |
JP2001163745A (en) * | 1999-12-08 | 2001-06-19 | Lion Corp | Patch agent for oral use |
IT1318649B1 (en) | 2000-07-28 | 2003-08-27 | Propharma S R L Ora Sinclair P | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MUCOSITES AND STOMATITIS. |
-
2001
- 2001-08-16 US US09/931,319 patent/US6585997B2/en not_active Expired - Lifetime
-
2002
- 2002-08-16 RU RU2004107575/15A patent/RU2343903C2/en not_active IP Right Cessation
- 2002-08-16 IL IL16041902A patent/IL160419A0/en unknown
- 2002-08-16 CA CA002459692A patent/CA2459692A1/en not_active Abandoned
- 2002-08-16 AU AU2002326664A patent/AU2002326664B2/en not_active Ceased
- 2002-08-16 HU HU0401281A patent/HUP0401281A3/en unknown
- 2002-08-16 JP JP2003520708A patent/JP2005504763A/en active Pending
- 2002-08-16 CN CN201010171156A patent/CN101849924A/en active Pending
- 2002-08-16 MX MXPA04001491A patent/MXPA04001491A/en unknown
- 2002-08-16 KR KR10-2004-7002303A patent/KR20040039290A/en not_active Application Discontinuation
- 2002-08-16 WO PCT/US2002/026083 patent/WO2003015748A2/en active IP Right Grant
- 2002-08-16 EP EP02761390A patent/EP1418889A2/en not_active Withdrawn
- 2002-08-16 NZ NZ531766A patent/NZ531766A/en not_active IP Right Cessation
- 2002-08-16 CN CNA028183274A patent/CN1738599A/en active Pending
- 2002-08-16 PL PL02373327A patent/PL373327A1/en unknown
-
2003
- 2003-05-23 US US10/444,512 patent/US20040062724A1/en not_active Abandoned
-
2004
- 2004-02-16 IS IS7155A patent/IS7155A/en unknown
- 2004-02-16 IL IL160410A patent/IL160410A/en not_active IP Right Cessation
- 2004-03-15 ZA ZA200402067A patent/ZA200402067B/en unknown
-
2010
- 2010-02-26 JP JP2010041418A patent/JP2010159268A/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513243A (en) * | 1983-06-08 | 1985-04-23 | Westinghouse Electric Corp. | Core form transformer for selective cancellation of subsynchronous resonance |
US4713243A (en) * | 1986-06-16 | 1987-12-15 | Johnson & Johnson Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
US5437857A (en) * | 1989-05-24 | 1995-08-01 | American Dental Association Health Foundation | Methods and compositions for mineralizing and fluoridating calcified tissues |
US6056930A (en) * | 1989-05-24 | 2000-05-02 | American Dental Association Health Foundation | Methods and compositions for mineralizing and fluoridating calcified tissues |
US6649147B1 (en) * | 1999-07-02 | 2003-11-18 | The Procter & Gamble Company | Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip |
US20030133884A1 (en) * | 2000-03-17 | 2003-07-17 | Sug-Youn Chang | Patches for teeth whitening |
US6682721B2 (en) * | 2000-03-17 | 2004-01-27 | Lg Household & Healthcare Ltd. | Patches for teeth whitening |
US6419906B1 (en) * | 2001-03-12 | 2002-07-16 | Colgate Palmolive Company | Strip for whitening tooth surfaces |
US6946142B2 (en) * | 2001-06-23 | 2005-09-20 | Lg Household & Healthcare Ltd. | Multi-layer patches for teeth whitening |
US20060073174A1 (en) * | 2001-08-16 | 2006-04-06 | Access Pharmaceuticals, Inc. | Adherent and erodible film to treat a moist surface of a body tissue |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070003495A1 (en) * | 1997-06-06 | 2007-01-04 | The Procter & Gamble Company | Methods for whitening teeth |
USRE42126E1 (en) | 1999-07-02 | 2011-02-08 | The Procter & Gamble Company | Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip |
US10493016B2 (en) | 2002-09-11 | 2019-12-03 | The Procter & Gamble Company | Tooth whitening product |
US20050100515A1 (en) * | 2002-09-11 | 2005-05-12 | The Procter & Gamble Company | Tooth whitening products |
US9554976B2 (en) | 2002-09-11 | 2017-01-31 | The Procter & Gamble Company | Tooth whitening product |
US20040265245A1 (en) * | 2003-05-27 | 2004-12-30 | Allred Peter M. | Substantially solid bleaching or treatment compositions in the form of inserts for dental trays, and kits comprising such inserts and trays |
US7172423B2 (en) | 2003-05-27 | 2007-02-06 | Ultradent Products, Inc. | Substantially solid bleaching or treatment compositions in the form of inserts for dental trays, and kits comprising such inserts and trays |
US20050081760A1 (en) * | 2003-07-01 | 2005-04-21 | Leng Lu H. | Table top |
US20050072369A1 (en) * | 2003-09-18 | 2005-04-07 | Goossen Theodorus Jozef | Submergible terrarium |
US20070218015A1 (en) * | 2003-11-03 | 2007-09-20 | Craig Hardy | Tooth-Whitening Composition |
US20050196358A1 (en) * | 2004-03-03 | 2005-09-08 | Constantine Georgiades | Film products having controlled disintegration properties |
US20050196348A1 (en) * | 2004-03-03 | 2005-09-08 | Constantine Georgiades | Stabilized peroxide compositions |
US20050196354A1 (en) * | 2004-03-03 | 2005-09-08 | Andre Soshinsky | Film compositions |
US20050196350A1 (en) * | 2004-03-03 | 2005-09-08 | Constantine Georgiades | Stabilized peroxide compositions |
US20070190125A1 (en) * | 2004-03-03 | 2007-08-16 | Constantine Georgiades | Positioning feature for aiding use of film or strip product |
US20080003248A1 (en) * | 2004-03-03 | 2008-01-03 | Constantine Georgiades | Whitening products |
US20070269519A1 (en) * | 2004-03-03 | 2007-11-22 | Constantine Georgiades | Whitening products |
WO2005102254A1 (en) * | 2004-04-08 | 2005-11-03 | The Procter & Gamble Company | Tooth whitening products |
WO2005110344A1 (en) | 2004-05-10 | 2005-11-24 | Colgate-Palmolive Company | Multilayer tooth whitening strips |
US20080317797A1 (en) * | 2004-06-09 | 2008-12-25 | Lornamead Brands, Inc. | Tooth whitening products and methods of making the same |
US20050276760A1 (en) * | 2004-06-09 | 2005-12-15 | Lornamead Brands, Inc. | Tooth for whitening products and methods of making the same |
US9149417B2 (en) | 2004-06-09 | 2015-10-06 | Lornamead Brands, Inc. | Tooth whitening products and methods of making the same |
US10350238B2 (en) | 2004-08-02 | 2019-07-16 | Glaxosmithkline Consumer Healthcare Holdings (Us) Llc | Method of treating xerostomia |
AU2005268926B2 (en) * | 2004-08-02 | 2011-10-13 | Glaxosmithkline Consumer Healthcare (Uk) Ip Limited | Novel composition for xerostomia |
US20080317703A1 (en) * | 2004-08-02 | 2008-12-25 | Gertrud Kawa | Novel Composition for Xerostomia |
US9044500B2 (en) | 2004-08-02 | 2015-06-02 | Glaxosmithkline Consumer Healthcare Gmbh & Co Kg | Composition for xerostomia |
WO2006013081A1 (en) * | 2004-08-02 | 2006-02-09 | Glaxo Group Limited | Novel composition for xerostomia |
US20080286317A1 (en) * | 2004-10-13 | 2008-11-20 | Lts Lohmann Therapie-Systeme Ag | Self-Adhesive Film for Teeth |
US10039711B2 (en) * | 2004-10-13 | 2018-08-07 | Lts Lohmann Therapie-Systeme Ag | Self-adhesive film for teeth |
US8137658B2 (en) | 2005-06-28 | 2012-03-20 | Isp Investments Inc. | Tooth whitening compositions |
US20070140985A1 (en) * | 2005-12-21 | 2007-06-21 | Boyd Thomas J | Cleaning and/or Polishing Compositions and Methods of Use Thereof |
US8741266B2 (en) | 2005-12-21 | 2014-06-03 | Colgate-Palmolive Company | Cleaning and/or polishing compositions and methods of use thereof |
WO2007076396A2 (en) | 2005-12-21 | 2007-07-05 | Colgate-Palmolive Company | Cleaning and/or polishing compositions and methods for use thereof |
AU2007272773B2 (en) * | 2006-07-14 | 2011-03-31 | Colgate-Palmolive Company | Methods of making compositions comprising films |
US9682256B2 (en) | 2006-07-14 | 2017-06-20 | Colgate-Palmolive Company | Methods of making compositions comprising films |
US20080014224A1 (en) * | 2006-07-14 | 2008-01-17 | Boyd Thomas J | Methods of Making Compositions Comprising Films |
WO2008008617A2 (en) | 2006-07-14 | 2008-01-17 | Colgate-Palmolive Company | Methods of making compositions comprising films |
WO2008157033A1 (en) * | 2007-06-20 | 2008-12-24 | Mcneil-Ppc, Inc | Products for whitening teeth |
EP2113238A1 (en) * | 2007-06-21 | 2009-11-04 | McNeil-PPC, Inc. | Products for whitening teeth |
RU2482836C1 (en) * | 2009-04-02 | 2013-05-27 | Колгейт-Палмолив Компани | Consumer products changing colour |
US9138384B2 (en) | 2009-04-02 | 2015-09-22 | Colgate-Palmolive Company | Color changing consumer products |
US8647648B2 (en) | 2009-04-02 | 2014-02-11 | Colgate-Palmolive Company | Color changing consumer products |
US9271906B2 (en) | 2010-11-08 | 2016-03-01 | Colgate-Palmolive Company | Oral compositions containing microaggregates |
WO2012064319A1 (en) | 2010-11-08 | 2012-05-18 | Colgate-Palmolive Company | Oral compositions containing microaggregates |
WO2012082098A1 (en) | 2010-12-13 | 2012-06-21 | Colgate-Palmolive Company | Oral compositions and method for producing thereof |
US9259377B2 (en) | 2010-12-13 | 2016-02-16 | Colgate-Palmolive Company | Oral compositions and method for producing thereof |
US9675540B2 (en) | 2010-12-13 | 2017-06-13 | Colgate-Palmolive Company | Oral compositions and method for producing thereof |
WO2012082103A1 (en) | 2010-12-13 | 2012-06-21 | Colgate-Palmolive Company | Oral compositions and method for producing thereof |
WO2012082101A1 (en) | 2010-12-13 | 2012-06-21 | Colgate-Palmolive Company | Oral compositions and method for producing thereof |
US9205058B2 (en) | 2011-06-27 | 2015-12-08 | Industry-Academic Cooperation Foundation, Chosun University | Tape-type fluorine preparation using biodegradable polymer and method of preparing the same |
WO2013002505A1 (en) * | 2011-06-27 | 2013-01-03 | 조선대학교 산학협력단 | Tape-type fluorine preparation using a biodegradable polymer material, and method for producing same |
KR101328162B1 (en) | 2011-06-27 | 2013-11-13 | 조선대학교산학협력단 | fluorine agent of tape type using biodegradable polymers and manufacturing method thereof |
WO2013087623A2 (en) | 2011-12-12 | 2013-06-20 | Glaxo Group Limited | Novel composition |
EP4385458A1 (en) | 2022-12-14 | 2024-06-19 | vVardis AG | Oral film with multiple regions for therapy of periodontal and dental diseases or disorders |
WO2024126751A1 (en) | 2022-12-14 | 2024-06-20 | vVardis AG | Oral film with multiple regions for therapy of periodontal and dental diseases or disorders |
Also Published As
Publication number | Publication date |
---|---|
KR20040039290A (en) | 2004-05-10 |
PL373327A1 (en) | 2005-08-22 |
ZA200402067B (en) | 2005-05-28 |
AU2002326664B2 (en) | 2008-03-06 |
EP1418889A2 (en) | 2004-05-19 |
US6585997B2 (en) | 2003-07-01 |
CA2459692A1 (en) | 2003-02-27 |
IL160419A0 (en) | 2004-09-27 |
MXPA04001491A (en) | 2004-05-17 |
WO2003015748A3 (en) | 2003-12-04 |
CN1738599A (en) | 2006-02-22 |
IL160410A (en) | 2009-08-03 |
US20030044446A1 (en) | 2003-03-06 |
WO2003015748A2 (en) | 2003-02-27 |
RU2004107575A (en) | 2005-04-20 |
JP2010159268A (en) | 2010-07-22 |
IL160410A0 (en) | 2004-09-27 |
HUP0401281A3 (en) | 2008-04-28 |
IS7155A (en) | 2004-02-16 |
HUP0401281A2 (en) | 2004-11-29 |
JP2005504763A (en) | 2005-02-17 |
CN101849924A (en) | 2010-10-06 |
NZ531766A (en) | 2005-12-23 |
RU2343903C2 (en) | 2009-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040062724A1 (en) | Erodible film for treating the surfaces of teeth | |
EP2206490A2 (en) | Adherent and erodible film to treat a moist surface of a body tissue | |
JP5599548B2 (en) | Hydrogel composition having a corrosive backing member | |
EP1401385B1 (en) | Multiple-layered patches for teeth whitening | |
US9149417B2 (en) | Tooth whitening products and methods of making the same | |
JP2007505135A5 (en) | ||
US20090238778A1 (en) | Tooth whitening compositions, delivery systems and methods | |
EP1736135A1 (en) | Oral care compositions, devices, and methods of using the same | |
JP2006528984A (en) | Hydrogel composition exhibiting phase separation | |
JPH09504810A (en) | Water-soluble pressure sensitive mucoadhesive | |
WO2007062414A1 (en) | Hydrogel sheets and shapes for oral care | |
AU2009202487A1 (en) | Teeth bleaching compositions and devices | |
KR20210024080A (en) | Oral composition and mucoadhesive thin film formed therefrom | |
US20060018845A1 (en) | Tooth whitening | |
KR20210135976A (en) | Oral formulation comprising hardening composition having ointment form | |
US20040219190A1 (en) | Multi-layer transenamel bleaching system | |
KR100550065B1 (en) | Teeth Whitening Patches with Hydrogel Matrix | |
KR100796385B1 (en) | Dry Thin Film Teeth Whitening Agent | |
JP2000063268A (en) | Oral mucosa adhesion-type controlled release troche and periodontal disease therapeutic agent | |
JP2000178185A (en) | Oral mucous membrane-adhering type sustained release tablet | |
EP1715835B1 (en) | Tooth-whitening composition | |
KR102514119B1 (en) | Dental wrap, dental kit comprising the same, method of using the same, and method for whitening teeth using the same | |
JPH0696518B2 (en) | Oral formulation | |
CA3106007A1 (en) | Dental wrap, dental kit comprising the same, method of using the same, and method for whitening teeth using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ACCESS PHARMACEUTICALS, INC., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORO, DANIEL G.;CALLAHAN, ERNEST HOWARD JR.;NOWOTNIK, DAVID P.;REEL/FRAME:014526/0487 Effective date: 20030924 |
|
AS | Assignment |
Owner name: ULURU INC., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ACCESS PHARMACEUTICALS, INC.;REEL/FRAME:017706/0576 Effective date: 20060530 |
|
AS | Assignment |
Owner name: ULURU INC., TEXAS Free format text: CONVEYANCE OF ALL RIGHT, TITLE AND INTEREST TO THE CORRESPONDING FOREIGN PATENTS AND PENDING APPLICATIONS TO THE RIGHTS PREVIOUSLY RECORDED ON REEL;ASSIGNOR:ACCESS PHARMACEUTICALS, INC.;REEL/FRAME:018015/0043 Effective date: 20060725 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |